HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Diverticular disease as a chronic illness: evolving epidemiologic and clinical insights.

Abstract
Diverticular disease imposes a significant burden on Western and industrialized societies. The traditional pathogenesis model posits that low dietary fiber predisposes to diverticulosis, and fecalith obstruction prompts acute diverticulitis that is managed with broad-spectrum antibiotics or surgery. However, a growing body of knowledge is shifting the paradigm of diverticular disease from an acute surgical illness to a chronic bowel disorder composed of recurrent abdominal symptoms and considerable psychosocial impact. New research implicates a role for low-grade inflammation, sensory-motor nerve damage, and dysbiosis in a clinical picture that mimics irritable bowel syndrome (IBS) and even inflammatory bowel disease (IBD). Far from being an isolated event, acute diverticulitis may be the catalyst for chronic symptoms including abdominal pain, cramping, bloating, diarrhea, constipation, and "post-diverticulitis IBS." In addition, studies reveal lower health-related quality of life in patients with chronic diverticular disease vs. controls. Health-care providers should maintain a high index of suspicion for the multifaceted presentations of diverticular disease, and remain aware that it might contribute to long-term emotional distress beyond traditional diverticulitis attacks. These developments are prompting a shift in therapeutic approaches from widespread antimicrobials and supportive care to the use of probiotics, mesalamine, and gut-directed antibiotics. This review addresses the emerging literature regarding epidemiology, pathophysiology, and management of chronic, symptomatic diverticular disease, and provides current answers to common clinical questions.
AuthorsLisa L Strate, Rusha Modi, Erica Cohen, Brennan M R Spiegel
JournalThe American journal of gastroenterology (Am J Gastroenterol) Vol. 107 Issue 10 Pg. 1486-93 (Oct 2012) ISSN: 1572-0241 [Electronic] United States
PMID22777341 (Publication Type: Journal Article, Review)
Chemical References
  • Anti-Infective Agents
  • Anti-Inflammatory Agents, Non-Steroidal
  • Dietary Fiber
  • Gastrointestinal Agents
  • Rifamycins
  • Mesalamine
  • Rifaximin
Topics
  • Abdominal Pain (etiology)
  • Acute Disease
  • Age Distribution
  • Anti-Infective Agents (therapeutic use)
  • Anti-Inflammatory Agents, Non-Steroidal (therapeutic use)
  • Chronic Disease
  • Colic (etiology)
  • Colonoscopy
  • Constipation (etiology)
  • Diagnosis, Differential
  • Diarrhea (etiology)
  • Dietary Fiber (administration & dosage)
  • Diverticulitis (complications, diagnosis, drug therapy, epidemiology, physiopathology)
  • Diverticulitis, Colonic (diagnosis, epidemiology)
  • Gastrointestinal Agents (therapeutic use)
  • Gastrointestinal Motility
  • Health Status
  • Humans
  • Inflammatory Bowel Diseases (diagnosis, physiopathology)
  • Intestines (microbiology)
  • Irritable Bowel Syndrome (diagnosis, physiopathology)
  • Mesalamine (therapeutic use)
  • Metagenome
  • Patient Education as Topic
  • Probiotics (therapeutic use)
  • Quality of Life
  • Rifamycins (therapeutic use)
  • Rifaximin
  • Terminology as Topic

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: